Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 4,803 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Not applicable Interventional

Diabetes Visual Function Supplement Study

NCT01646047
View directory record Official record
Conditions
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions
multi-component nutritional supplement capsules, multi-component dietary supplement
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 25, 2026, 10:45 PM EDT
Withdrawn Not applicable Interventional

Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC)

NCT04240587
View directory record Official record
Conditions
Contact Allergy, Neuropathic Pain
Interventions
TrueTear™ intranasal neurostimulator (ITN)
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 25, 2026, 10:45 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma

NCT07772921
View directory record Official record
Conditions
Asthma
Interventions
tilrekimig, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Bakersfield, California • Miami, Florida • White Marsh, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 10:45 PM EDT
Completed No phase listed Observational

Blood Lymphocytes in Asthmatics Treated With Therapeutic Proteins

NCT04514926
View directory record Official record
Conditions
Asthma, Therapeutic Proteins
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 25, 2026, 10:45 PM EDT
Recruiting Not applicable Interventional

Hospital to Home Study: Trial to Optimize Transitions and Address Disparities in Asthma Care

NCT05991115
View directory record Official record
Conditions
Asthma, Asthma in Children
Interventions
Hospital to Home Transition (H2H)
Behavioral
Lead sponsor
Kavita Parikh
Other
Eligibility
4 Years to 12 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Pain Alleviating Strategies During Allergy Shots

NCT04181632
View directory record Official record
Conditions
Immunotherapy, Allergy
Interventions
Buzzy Bee with Ice pack, Buzzy Bee without Ice pack, Shot Blocker
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
4 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

NCT00690833
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
topical desonide hydrogel 0.05%
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity

NCT02476032
View directory record Official record
Conditions
Tooth Sensitivity
Interventions
Prof applied oxalate, Self applied oxalate, Prof applied placebo
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 25, 2026, 10:45 PM EDT
Withdrawn No phase listed Observational

Comparison of Microbiome Composition and Biomarkers in Pharmaco Resistant and Pharmaco-Sensitive Epilepsy

NCT04308252
View directory record Official record
Conditions
Epilepsy in Children, Pharmaco-Resistant Epilepsy
Interventions
Not listed
Lead sponsor
Senda Biosciences
Industry
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

NCT03822832
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
BI 655130, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 25, 2026, 10:45 PM EDT
Available No phase listed Expanded access

Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

NCT07216378
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Sebetralstat
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
2 Years to 11 Years
U.S. locations
6
States / cities
San Diego, California • Evansville, Indiana • Wheaton, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Glutamine and Insulin Sensitivity in Type I Diabetes

NCT01467063
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Glutamine, Placebo
Dietary Supplement
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

NCT00723489
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Live Yellow Fever Vaccine (YFV-17D), YFV-17D Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
27 Years to 43 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT04195698
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
33
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 25, 2026, 10:45 PM EDT
Terminated Phase 1 Interventional

MRI in Finding Hypoxia in Patients Undergoing Chemo and Radiation for Head and Neck Cancer

NCT00896350
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Standard Care Chemoradiation
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 25, 2026, 10:45 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

NCT03389893
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety/Tolerability of Ragweed MATA MPL

NCT00423787
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Ragweed MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
993 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Waterbury, Connecticut • Atlanta, Georgia • Conyers, Georgia + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 25, 2026, 10:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans

NCT02459106
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

NCT00953147
View directory record Official record
Conditions
Allergic Rhinitis, Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA 80 mcg, Ciclesonide HFA 160 mcg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
45
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

NCT01831817
View directory record Official record
Conditions
Dentinal Hypersensitivity
Interventions
5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice, 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice, Sodium monofluorophosphate dentifrice, Sodium Fluoride dentifrice
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 25, 2026, 10:45 PM EDT
Recruiting Not applicable Interventional

Mechanisms of Ultrasound Neuromodulation Effects in Diabetes

NCT06042517
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Ultrasound, OGTT with unlabeled glucose and liver NMR, OGTT with carbon-13 labeled glucose and liver NMR, CGM glucose reading, HEC - Hyperinsulinemic-Euglycemic-Clamp
Device · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 25, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

NUPRO Sensodyne Prophylaxis Paste With NovaMin Sensitivity Relief Study

NCT01669785
View directory record Official record
Conditions
Tooth Hypersensitivity
Interventions
Group C, Group A, Group B
Device
Lead sponsor
Dentsply International
Industry
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 25, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 25, 2026, 10:45 PM EDT